Abeona Therapeutics

Abeona Therapeutics Inc. (Nasdaq: ABEO) is a leading clinical stage company developing gene therapy and plasma-based therapies for severe and life-threatening rare genetic diseases. Abeona's lead programs are ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB), respectively. We are also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, Abeona is developing plasma protein therapies, including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD, using our proprietary SDF™ (Salt Diafiltration) ethanol-free process.

Dallas, US
6 (est)
Abeona Therapeutics was founded in 2013 and is headquartered in Dallas, US

Abeona Therapeutics Locations

Dallas, US

Abeona Therapeutics Metrics

Abeona Therapeutics Summary

Market capitalization

$204 M

Closing share price

Abeona Therapeutics's current market capitalization is $204 M.

Abeona Therapeutics Market Value History

Abeona Therapeutics Online Presence

Abeona Therapeutics News

Abeona Therapeutics Company Life

You may also be interested in